Estrella Immunopharma(ESLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ESLA Estrella Immunopharma

Market Closed 12-12 16:00:00 EST

1.73

-0.11

-5.98%

盘后1.73

+0.000.00%

16:20 EST

High1.84	Low1.67	Vol54.30K
Open1.79	D1 Closing1.84	Amplitude9.24%
Mkt Cap65.33M	Tradable Cap19.00M	Total Shares37.77M
T/O95.69K	T/O Rate0.49%	Tradable Shares10.99M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ESLA","market":"US","secType":"STK","nameCN":"Estrella Immunopharma","latestPrice":1.73,"timestamp":1765573200000,"preClose":1.84,"halted":0,"volume":54297,"hourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.73,"latestTime":"16:20 EST","volume":4,"amount":6.92,"timestamp":1765574400220},"delay":0,"floatShares":10985451,"shares":37765589,"eps":-0.367652,"marketStatus":"Market Closed","change":-0.11,"latestTime":"12-12 16:00:00 EST","open":1.79,"high":1.84,"low":1.67,"amount":95685.0555,"amplitude":0.092391,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.367652,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.84,"postHourTrading":{"tag":"盘后","latestPrice":1.73,"preClose":1.73,"latestTime":"16:20 EST","volume":4,"amount":6.92,"timestamp":1765574400220},"volumeRatio":0.34782669972683694},"requestUrl":"/m/hq/s/ESLA","defaultTab":"news","newsList":[{"id":"2588882658","title":"BRIEF-Estrella Advances Starlight-1 Trial Into Phase II Following Positive DSMB Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2588882658","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588882658?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:20","pubTimestamp":1764854450,"startTime":"0","endTime":"0","summary":"BRIEF-Estrella Advances Starlight-1 Trial Into Phase II Following Positive DSMB RecommendationDec 4 (Reuters) - Estrella Immunopharma Inc ESLA.O:ESTRELLA ADVANCES STARLIGHT-1 TRIAL INTO PHASE II FOLLO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0CS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2588884402","title":"Estrella Advances Starlight-1 Trial Into Phase Ii Following Positive Dsmb Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2588884402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588884402?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:01","pubTimestamp":1764853265,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0CS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2588188446","title":"Estrella Immunopharma Advances EB103 T-Cell Therapy to Phase II After Positive Safety Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2588188446","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588188446?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:00","pubTimestamp":1764853254,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. announced that its STARLIGHT-1 clinical trial has advanced to Phase II following a positive recommendation from an independent Data Safety Monitoring Board . The decision was based on safety data from the Phase I dose escalation phase, during which no treatment-related serious adverse events were reported among nine patients, and all evaluable patients in the high-dose cohort achieved a complete response at Month 1. The STARLIGHT-1 trial is evaluating EB103, a CD19-redirected ARTEMIS T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The expansion phase will further assess safety and preliminary efficacy, with results to be collected and used to inform future pivotal trial strategies. Results from the expansion phase have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gener","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDLPfxdQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2581049819","title":"Estrella Immunopharma Reports 100% Complete Response Rate in STARLIGHT-1 EB103 Trial Cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2581049819","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581049819?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:18","pubTimestamp":1762467480,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS T-cell therapy for patients with advanced B-cell Non-Hodgkin's Lymphomas . According to the company, all evaluable patients in this high-risk group-including those not suitable for commercial CD19 products and one with central nervous system involvement-achieved a 100% complete response rate at Month 1. No treatment-related serious adverse events were reported in this cohort. The results have been announced by the company, and a Data and Safety Monitoring Board will review the cumulative study data to determine the recommended Phase II dose for the trial's expansion phase. Further details are available under clinical trial identifier NCT06343311.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6zNthp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2580324895","title":"Estrella Immunopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2580324895","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580324895?lang=en_us&edition=fundamental","pubTime":"2025-11-04 00:32","pubTimestamp":1762187520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 03, 2025 11:32 ET (16:32 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA"],"gpt_icon":0},{"id":"2580573215","title":"Estrella Immunopharma completes second dose cohort in STARLIGHT-1 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2580573215","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580573215?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:10","pubTimestamp":1762175426,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma (ESLA) announced the completion of the second dose cohort in Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-completes-second-dose-cohort-in-starlight-1-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/estrella-immunopharma-completes-second-dose-cohort-in-starlight-1-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2580213658","title":"Estrella Immunopharma Reports 100% Complete Response Rate in Phase I EB103 Trial for Advanced B-Cell NHL","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213658","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580213658?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:02","pubTimestamp":1762174976,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for patients with advanced B-cell Non-Hodgkin's Lymphomas . According to the company, the study achieved a 100% complete response rate at Month 1 in all evaluable patients in this cohort, which included individuals with relapsed or refractory B-cell NHL who had failed multiple prior therapies and were considered high-risk, including one patient with central nervous system involvement. No treatment-related serious adverse events were reported. The data from this phase will be reviewed by an independent Data and Safety Monitoring Board to determine the recommended Phase II dose for the expansion phase of the trial. These results have already been announced by the company.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL6m4ZWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2580721341","title":"Estrella Immunopharma Inc - Study Achieves 100% Complete Response Rate at Month 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2580721341","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580721341?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:00","pubTimestamp":1762174808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA46JTBL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2580321344","title":"Estrella Immunopharma Inc - No Serious Adverse Events Reported in Study Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2580321344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580321344?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:00","pubTimestamp":1762174808,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA46JTBL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2580213832","title":"Estrella Immunopharma Completes Second Dose Cohort in Starlight-1 Trial of Eb103 With Complete Responses in All Evaluable Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213832","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580213832?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:00","pubTimestamp":1762174808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA46JTBL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2580213414","title":"Estrella Immunopharma Inc - Following the Completion of Dose Cohort, Dsmb to Review Study Data for Safety and Efficacy","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213414","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580213414?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:00","pubTimestamp":1762174808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nTUA46JTBL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2573672609","title":"BRIEF-Estrella Immunopharma Regains Compliance With Nasdaq Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2573672609","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573672609?lang=en_us&edition=fundamental","pubTime":"2025-10-06 20:22","pubTimestamp":1759753358,"startTime":"0","endTime":"0","summary":"BRIEF-Estrella Immunopharma Regains Compliance With Nasdaq Listing RequirementsOct 6 (Reuters) - Estrella Immunopharma Inc ESLA.O:ESTRELLA IMMUNOPHARMA REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREME","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA1KMPH6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2573485674","title":"Estrella Immunopharma Regains Nasdaq Compliance After Meeting Bid Price and Market Value Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2573485674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573485674?lang=en_us&edition=fundamental","pubTime":"2025-10-06 20:01","pubTimestamp":1759752066,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. , a clinical stage biopharmaceutical company, announced it has regained compliance with Nasdaq's listing requirements. The company received confirmation from Nasdaq's Listing Qualifications Department that it now meets the minimum bid price and market value of listed securities standards. This follows Estrella's recent efforts to strengthen its balance sheet and raise new capital to support development of its CD19 and CD22-targeted ARTEMIS T-cell therapies. With these matters resolved, Nasdaq has closed its review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via Business Wire  on October 06, 2025, and is solely respo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nNDL8kK4B1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2572559899","title":"Estrella Immunopharma Inc. Files Initial Statement of Beneficial Ownership for Director Dengyao Jia","url":"https://stock-news.laohu8.com/highlight/detail?id=2572559899","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572559899?lang=en_us&edition=fundamental","pubTime":"2025-10-02 01:25","pubTimestamp":1759339528,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing identifies Dengyao Jia as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL794BF3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"gpt_icon":0},{"id":"2571365028","title":"Estrella Immunopharma Regains Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2571365028","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571365028?lang=en_us&edition=fundamental","pubTime":"2025-09-30 05:49","pubTimestamp":1759182569,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma ( ($ESLA) ) has provided an announcement. Estrella Immunopharma, Inc. announced that it has regained compliance with Nasdaq’s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/estrella-immunopharma-regains-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/estrella-immunopharma-regains-nasdaq-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QLD","USJW.SI","ESLA","NQmain","BK4139","PSQ","TSYW.SI","NVIW.SI","USAW.SI","MNQmain","SQQQ","QID",".IXIC","TQQQ"],"gpt_icon":0},{"id":"2570830195","title":"Estrella Immunopharma Appoints Jia Dengyao to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2570830195","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570830195?lang=en_us&edition=fundamental","pubTime":"2025-09-27 05:26","pubTimestamp":1758921966,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. has announced the appointment of Jia Dengyao to its Board of Directors, effective immediately. Jia is not currently expected to join any board committees. The company has also entered into an indemnification agreement with Jia, similar to those in place with other non-employee directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nNDL2Kv5th:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0},{"id":"2559257466","title":"Estrella Immunopharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2559257466","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559257466?lang=en_us&edition=fundamental","pubTime":"2025-08-13 00:55","pubTimestamp":1755017700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESLA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 12, 2025 12:55 ET (16:55 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA"],"gpt_icon":0},{"id":"2557599395","title":"Estrella Immunopharma Inc. Faces Nasdaq Delisting Threat Over Market Value Non-Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2557599395","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557599395?lang=en_us&edition=fundamental","pubTime":"2025-08-07 18:07","pubTimestamp":1754561249,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma Inc. has announced that it received a notice from the Nasdaq Stock Market LLC on August 1, 2025, indicating non-compliance with Nasdaq Listing Rule 5550. The company failed to maintain the required minimum Market Value of Listed Securities  of $35 million for 30 consecutive business days, specifically from June 13 to July 31, 2025. While this notification does not immediately affect the company's listing, Estrella Immunopharma has been granted a 180-day period, until January 28, 2026, to meet the MVLS requirement by closing at or above $35 million for ten consecutive business days. The company is actively monitoring its MVLS and considering options to regain compliance, though there is no guarantee of success.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL3nvdvJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.estrellabio.com","stockEarnings":[{"period":"1week","weight":-0.1307},{"period":"1month","weight":-0.1762},{"period":"3month","weight":0.6476},{"period":"6month","weight":0.8021},{"period":"1year","weight":0.4009},{"period":"ytd","weight":0.4417}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":-0.019009},{"month":2,"riseRate":0.5,"avgChangeRate":-0.025426},{"month":3,"riseRate":0.5,"avgChangeRate":0.026432},{"month":4,"riseRate":0.75,"avgChangeRate":0.006035},{"month":5,"riseRate":0.25,"avgChangeRate":-0.040145},{"month":6,"riseRate":0.5,"avgChangeRate":0.017516},{"month":7,"riseRate":0.5,"avgChangeRate":0.07367},{"month":8,"riseRate":0.25,"avgChangeRate":-0.054345},{"month":9,"riseRate":0.75,"avgChangeRate":0.07408},{"month":10,"riseRate":0.6,"avgChangeRate":-0.005756},{"month":11,"riseRate":0.8,"avgChangeRate":0.071826},{"month":12,"riseRate":0.2,"avgChangeRate":-0.093392}],"exchange":"NASDAQ","name":"Estrella Immunopharma","nameEN":"Estrella Immunopharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Estrella Immunopharma(ESLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Estrella Immunopharma(ESLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Estrella Immunopharma,ESLA,Estrella Immunopharma股票,Estrella Immunopharma股票老虎,Estrella Immunopharma股票老虎国际,Estrella Immunopharma行情,Estrella Immunopharma股票行情,Estrella Immunopharma股价,Estrella Immunopharma股市,Estrella Immunopharma股票价格,Estrella Immunopharma股票交易,Estrella Immunopharma股票购买,Estrella Immunopharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Estrella Immunopharma(ESLA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Estrella Immunopharma(ESLA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction